Figure 5.
Cumulative incidence of nonpersistence.
Notes: Between baseline and month 6, seven patients had discontinued fingolimod; three for months 6–12, five for months 12–18, and four for months 18–24. The gray shaded area represents 95% CIs.
Cumulative incidence of nonpersistence.
Notes: Between baseline and month 6, seven patients had discontinued fingolimod; three for months 6–12, five for months 12–18, and four for months 18–24. The gray shaded area represents 95% CIs.